Motherwort and astragalus capsule used for treating prostatic hyperplasia

Abstract

The invention relates to a motherwort and astragalus capsule used for treating prostatic hyperplasia and can effectively solve the treatment problem of benign prostatic hyperplasia. The technical schemes are as follows: the motherwort and astragalus capsule is prepared from motherwort extract, astragalus extract, starch and talcum powder, wherein the weight ratio of the motherwort extract to the astragalus extract is (4-6):(6-4); and the motherwort and astragalus capsule is prepared by crushing the motherwort extract and the astragalus extract, screening with a 100-mesh sieve, mixing uniformly, then adding starch and talcum powder, uniformly mixing, wherein the addition amount of starch and talcum powder is not more than 10% the total weight of the motherwort extract, astragalus extract, starch and talcum powder and the weight ratio of starch to talcum powder is 1:1, granulating and encapsulating. The motherwort and astragalus capsule provided by the invention has the advantages of simple preparation method, proper compatibility, good efficacy, no toxic or side effect and significant treatment effect on benign prostatic hyperplasia, is innovative in the treatment of benign prostatic hyperplasia, and has huge economic and social benefits.

Description

technical field [0001] The invention relates to medicine, in particular to a Yiqi capsule for treating benign prostatic hyperplasia. Background technique [0002] Benign prostatic hyperplasia (BPH), or benign prostatic hyperplasia (BPH), is defined by the International Benign Prostatic Hyperplasia Advisory Committee as: the presence of objective evidence of benign prostatic growth or prostatic transition zone growth, with lower urinary tract symptoms (LUTS) or worsening lower urinary tract symptoms and upper urinary tract impairment with bladder outlet obstruction (BOO) [1] . Men can have different degrees of prostate hyperplasia after the age of 35, and benign prostatic hyperplasia will appear in any man after the age of 50; generally, clinical symptoms such as dysuria will appear after the age of 50, and the incidence rate continues to increase with age. According to foreign statistics, the incidence rate is about 50% over the age of 50, and 80% to 100% of the crowd over...

AI Technical Summary

Problems solved by technology

However, because the treatment of benign prostatic hyperplasia takes a long time, long-term medication is required, adverse reactions of western medicine, unstable curative effect, high cost, etc., are often subject to many restrictions

Traditional Chinese medicine classifies benign prostatic hyperplasia into the category of "diarrhea" and "drenching syndrome". Promoting blood circulation to remove blood stasis, promoting diuresis to relieve stranguria, clearing away heat and detoxification, nourishing the spleen and kidney, etc., but the treatment cycle is long and the curative effect needs to be further improved

Images